Session
Pharmaceutical and Natural Sciences
Description
This comprehensive review explores the critical role of ribosomes in cancer development and treatment, with a particular focus on acute lymphoblastic leukemia (ALL). The human ribosome, essential for protein synthesis, is implicated in cancer transformation through its interaction with oncoproteins. The review examines various strategies targeting ribosome biogenesis and cancer cell proliferation, including drugs and molecular therapies. It provides an in-depth analysis of ALL, the most common pediatric malignancy, discussing its prevalence, genetic characteristics, and treatment approaches. The review covers recent advancements in ALL classification, risk assessment, and targeted therapies, including tyrosine kinase inhibitors, CAR T-cell therapy, and gene therapy. Special attention is given to ALL in children with Down syndrome and the associated challenges. The paper also delves into ribosome biogenesis, ribosomopathies, and their connections to various cancers and rare genetic diseases. It explores RNA modifications, protein post-translational modifications, and their roles in cellular processes. The review discusses the tumor suppressor protein p53 and its implications in cancer and metabolic disorders. Additionally, it examines specific ribosomal proteins and their functions in various diseases. The abstract concludes by highlighting the importance of pharmacogenetics in ALL treatment and the potential of combination therapies in the era of precision medicine.
Keywords:
ALL classification, p53, RNA modifications.
Proceedings Editor
Edmond Hajrizi
ISBN
978-9951-982-15-3
Location
UBT Kampus, Lipjan
Start Date
25-10-2024 9:00 AM
End Date
27-10-2024 6:00 PM
DOI
10.33107/ubt-ic.2024.166
Recommended Citation
Temaj, Anjeza; Gashi, Yllka; Selmani, Driton; Xharra, Shefki; Xharra, Kumrije; and Temaj, Gazmend, "The Role of Ribosomes in Cancer and Acute Lymphoblastic Leukemia: From Biogenesis to Targeted Therapies" (2024). UBT International Conference. 11.
https://knowledgecenter.ubt-uni.net/conference/2024UBTIC/PNS/11
Included in
The Role of Ribosomes in Cancer and Acute Lymphoblastic Leukemia: From Biogenesis to Targeted Therapies
UBT Kampus, Lipjan
This comprehensive review explores the critical role of ribosomes in cancer development and treatment, with a particular focus on acute lymphoblastic leukemia (ALL). The human ribosome, essential for protein synthesis, is implicated in cancer transformation through its interaction with oncoproteins. The review examines various strategies targeting ribosome biogenesis and cancer cell proliferation, including drugs and molecular therapies. It provides an in-depth analysis of ALL, the most common pediatric malignancy, discussing its prevalence, genetic characteristics, and treatment approaches. The review covers recent advancements in ALL classification, risk assessment, and targeted therapies, including tyrosine kinase inhibitors, CAR T-cell therapy, and gene therapy. Special attention is given to ALL in children with Down syndrome and the associated challenges. The paper also delves into ribosome biogenesis, ribosomopathies, and their connections to various cancers and rare genetic diseases. It explores RNA modifications, protein post-translational modifications, and their roles in cellular processes. The review discusses the tumor suppressor protein p53 and its implications in cancer and metabolic disorders. Additionally, it examines specific ribosomal proteins and their functions in various diseases. The abstract concludes by highlighting the importance of pharmacogenetics in ALL treatment and the potential of combination therapies in the era of precision medicine.